NASDAQ : RARE
Ultragenyx Pharmaceutical Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 16.78 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.65B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.58B |
| Enterprise Value | 2.35B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 98.29M |
| Shares Outstanding | 98.29M |
| Shares Change (YoY) | +4.22% |
| Shares Change (QoQ) | +1.29% |
| Owned by Insiders (%) | 3.61% |
| Owned by Institutions (%) | 97.08% |
| Float | 74.10M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.21 |
| Forward PS | 1.82 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 3.28 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.73 |
| Quick Ratio | 1.41 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -6.47 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -24.22% |
| Return on Invested Capital (ROIC) | -31.77% |
| Return on Capital Employed (ROCE) | -54.55% |
| Weighted Average Cost of Capital (WACC) | 5.72% |
| Revenue Per Employee | $522,976 |
| Profits Per Employee | -$427,425 |
| Employee Count | 1,371 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 16.42 |
Taxes
| Measure | Value |
|---|
| Income Tax | 4.00M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.36 |
| 52-Week Price Change | -53.45% |
| 50-Day Moving Average | 17.01 |
| 200-Day Moving Average | 22.90 |
| Relative Strength Index (RSI) | 49.82 |
| Average Volume (20 Days) | 3,370,305 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 20.15M |
| Short Previous Month | 20.35M |
| Short % of Shares Out | 20.50% |
| Short % of Float | 27.19% |
| Short Ratio (days to cover) | 3.79 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 717.00M |
| Gross Profit | -149.00M |
| Operating Income | -498.00M |
| Pretax Income | -582.00M |
| Net Income | -586.00M |
| EBITDA | -465.00M |
| EBIT | -498.00M |
| Loss Per Share | -$5.83 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 292.00M |
| Total Debt | 1.20B |
| Net Cash | -766.00M |
| Net Cash Per Share | -$7.79 |
| Equity (Book Value) | -284.00M |
| Book Value Per Share | -2.96 |
| Working Capital | 255.00M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -485.00M |
| Capital Expenditures | -4.00M |
| Depreciation & Amortization | 33.00M |
| Net Borrowing | n/a |
| Free Cash Flow | -489.00M |
| FCF Per Share | -$4.98 |
Margins
| Measure | Value |
|---|
| Gross Margin | -20.78% |
| Operating Margin | -69.46% |
| Pretax Margin | -81.17% |
| Profit Margin | -81.73% |
| EBITDA Margin | -64.85% |
| EBIT Margin | -69.46% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.22% |
| Shareholder Yield | n/a |
| Earnings Yield | -36.20% |
| FCF Yield | -30.90% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $26.25 |
| Price Target Difference | 63.04% |
| Analyst Consensus | Buy |
| Analyst Count | 21 |
| Revenue Growth Forecast (3Y) | 20.21% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -4.78 |
| Piotroski F-Score | 3 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |